D.T. Geraets

TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.

TL;DR: In view of the results of HPV DNA and high proportion of p16INK4a overexpression, infection by HPV is most likely to be a necessary cause for anal cancers in both men and women.

TL;DR: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3 and the most common type detected, HPV16 was the most frequently type detected in both precancerous and cancerous lesions.

TL;DR: VALGENT extends current guidelines for high-risk HPV test validation in cervical cancer screening and has produced a large study resource for test comparison and validation of HPV assays in general and HPV genotyping tests in particular.

TL;DR: The study demonstrated lack of co-infection between Human Papillomavirus and C. trachomatis in in-situ and invasive adenocarcinoma of the uterine cervix, suggesting the role of Ct as a carcinogenetic co-factor may be restricted to cervical squamous cell carcinomas.